News & Analysis on Clinical Trial Services & Contract Research And Development
Cardinal Health saw a double-digit hike in fiscal third quarter revenues mirrored by a decline in operating earnings, as gains in its drug distribution and medical products businesses were offset by lower profits in sterile manufacturing and...
Lonza is planning a major exansion of its peptides manufacturing capacities at Visp, Switzerland, in response to what it said was 'the increased demand for peptide active pharmaceutical ingredients worldwide'.
The contract manufacturing sector lagged behind the rest of the outsourcing industry serving the pharmaceutical sector in 2004, but there are encouraging signs for the future, reports Phil Taylor.
A worldwide agreement to develop and commercialise a fully human monoclonal antibody that could have therapeutic potential in the treatment of T-cell mediated diseases has been agreed between Serono and Genmab.
GlaxoSmithKline has announced plans to acquire the Corixa Corporation, which represents an important strategic deal for GSK's vaccines division, GSK Bio. The division is the only major vaccine maker with active R&D programs for HIV, malaria, and TB...
German drug development company BioGenerix has earmarked up to $61.5 million (€48m) to develop a new version of an already-marketed biologic drug using a pegylation technology developed by US firm Neose, reports Phil Taylor.
GlaxoSmithKline has signed a consent decree with the US Food and Drug Administration to correct manufacturing deficiencies at its Cidra, Puerto Rico facility, but could be in a position to return two drugs made at the plant to market within the next...
Waters Corporation has launched the MassTrak Clinical Solutions, a system that is aimed at monitoring and measuring drug therapies, performing toxicology screening and quantifying biomarkers quickly, reliably and accurately.
Researchers in the US have found that blocking the COX-1, not COX-2 enzyme, might lead the way to prevent and treat the most common and fatal form of ovarian cancer.
Celera Genomics have filed an Investigational New Drug (IND) application for a novel histone deacetylase (HDAC) inhibitor that has proved effective in inhibiting cancer cell proliferation. The filing also signifies Celera's transformation from selling...